Your browser doesn't support javascript.
loading
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
Burman, Joachim; Raininko, Raili; Blennow, Kaj; Zetterberg, Henrik; Axelsson, Markus; Malmeström, Clas.
Afiliación
  • Burman J; Department of Neurosciences, Uppsala University, Uppsala, Sweden; Department of Neurology, Uppsala University Hospital, Uppsala, Sweden. Electronic address: joachim.burman@neuro.uu.se.
  • Raininko R; Department of Radiology, Uppsala University, Uppsala, Sweden. Electronic address: raili.raininko@radiol.uu.se.
  • Blennow K; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. Electronic address: kaj.blennow@neuro.gu.se.
  • Zetterberg H; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom. Electronic address: henrik.z
  • Axelsson M; Department of Clinical Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. Electronic address: markus.axelsson@neuro.gu.se.
  • Malmeström C; Department of Clinical Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. Electronic address: clas.malmestrom@neuro.gu.se.
J Neuroimmunol ; 292: 52-7, 2016 Mar 15.
Article en En | MEDLINE | ID: mdl-26943959
ABSTRACT
YKL-40 (CHI3L1) is a glycoprotein predominantly produced by reactive astrocytes in chronic active MS lesions, which are common in secondary progressive MS. In this study, YKL-40 was investigated in different stages of MS and in relation to MRI findings. YKL-40 levels in CSF samples from two independent patient cohorts of MS patients were determined with ELISA. CSF YKL-40 was increased in patients with active relapsing-remitting MS and correlated with the number of gadolinium enhancing lesions. Patients with secondary progressive MS had similar high levels of YKL-40, whereas not active relapsing-remitting MS patients had YKL-40 levels comparable to healthy controls.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Crónica Progresiva / Adipoquinas / Lectinas Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Neuroimmunol Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Crónica Progresiva / Adipoquinas / Lectinas Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Neuroimmunol Año: 2016 Tipo del documento: Article